You are here

Novan

Second-quarter catalysts for the smaller players

Second-quarter catalysts for the smaller players

EP Vantage

Fulcrum Therapeutics

Gemini Therapeutics

Flag link:

Novan crushed by phase 3 failures of antiviral gel

Novan crushed by phase 3 failures of antiviral gel

Fierce Biotech

molluscum contagiosum

Flag link:

Ligand acquires milestone and royalty rights to SB206 from Novan

Ligand acquires milestone and royalty rights to SB206 from Novan

Pharmaceutical Business Review

Ligand Pharmaceuticals

skin infections

Flag link:

Novan spikes on positive antifungal results

Novan spikes on positive antifungal results

BioPharma Dive

Flag link:

Novan’s Topical Treatment Shows Efficacy Against Drug-resistant Bugs

Novan’s Topical Treatment Shows Efficacy Against Drug-resistant Bugs

Drug Discovery and Development

antibiotic resistance

Flag link: